Quest Diagnostics Incorporated (DGX), a provider of diagnostic information services, Tuesday said it partnered with The University of Texas MD Anderson Cancer Center to develop a multi-cancer stratification (MCaST) blood test. Quest will develop a blood test to detect one or more cancers, including colorectal, lung, breast, pancreatic, ovarian, liver, prostate, esophageal and stomach, based on MD Anderson technology. Assuming successful test validation, the parties may agree for Quest to exercise rights to commercialize the test, with the goal of making it available to providers in North America in 2026, Quest said in a statement.
"Building on proteomics discoveries from Dr. Hanash and his team, Quest intends to create a simple blood test anyone can conveniently access and reasonably afford to identify risk of a range of cancers. A patient identified with elevated risk may be more inclined to pursue preventive cancer screening or other medical assessments that could identify cancer in early, more treatable stages of disease," said Mark Gardner, senior vice president, Oncology, Genomics and R&D, Quest Diagnostics.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.